Stockscreener 앱 받기
8.95
3.60%
-0.345
전일 마감가:
$9.295
열려 있는:
$9.3
하루 거래량:
183.26K
Relative Volume:
0.04
시가총액:
$85.03M
수익:
-
순이익/손실:
$-6.42M
주가수익비율:
-1.5978
EPS:
-5.6013
순현금흐름:
$-7.45M
1주 성능:
-8.29%
1개월 성능:
-37.30%
6개월 성능:
-25.52%
1년 성능:
-62.49%
1일 변동 폭
$8.7562
$9.4419
1주일 범위
$8.7562
$10.40
52주 변동 폭
$1.80
$25.69
Cervomed Inc Stock (CRVO) Company Profile
명칭
Cervomed Inc
전화
(617) 744-4400
주소
20 PARK PLAZA, BOSTON
CRVO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRVO
Cervomed Inc
|
9.0023 | 85.03M | 0 | -6.42M | -7.45M | -5.6013 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.05 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
583.76 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
599.84 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.78 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
253.34 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Cervomed Inc Stock (CRVO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-13 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2024-12-17 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-12-11 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2024-12-11 | 다운그레이드 | Morgan Stanley | Overweight → Underweight |
| 2024-12-10 | 다운그레이드 | D. Boral Capital | Buy → Hold |
| 2024-12-06 | 개시 | ROTH MKM | Buy |
| 2024-12-05 | 개시 | H.C. Wainwright | Buy |
| 2024-09-18 | 개시 | Chardan Capital Markets | Buy |
| 2024-07-26 | 개시 | Morgan Stanley | Overweight |
| 2024-02-15 | 개시 | Canaccord Genuity | Buy |
| 2020-11-17 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2018-03-21 | 개시 | H.C. Wainwright | Buy |
모두보기
Cervomed Inc 주식(CRVO)의 최신 뉴스
What Will CervoMed Inc (NASDAQ: CRVO) Be Like In 2025 - Stocksregister
CervoMed Inc. Announces Executive Appointments and Officer Departure By Investing.com - Investing.com South Africa
CervoMed Announces Executive Appointments and Changes - MSN
CervoMed Inc. Announces Executive Appointments and Officer Departure - Investing.com Australia
CervoMed (CRVO) to Present Key Findings on Dementia Drug at Inte - GuruFocus
CervoMed (CRVO) Reports Positive Phase 2b Results for Neflamapim - GuruFocus
CervoMed Reports Positive Phase 2b Trial Results - TipRanks
Brokerages Set CervoMed Inc. (NASDAQ:CRVO) Price Target at $27.50 - Defense World
CervoMed To Present Phase 2b Data On Neflamapimod's Impact On DLB At AD/PD 2025 - Nasdaq
CervoMed to present results on Phase 2b RewinD-LB study - TipRanks
Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD™ 2025 - GlobeNewswire
CervoMed Inc. to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD 2025 - marketscreener.com
Virtu Financial LLC Invests $26,000 in CervoMed Inc. (NASDAQ:CRVO) - Defense World
Biotech Stocks Q1 2025 Recap: Winners And Underperformers - Seeking Alpha
CervoMed (CRVO) Projected to Post Quarterly Earnings on Friday - Defense World
FY2025 EPS Estimates for CervoMed Lowered by Chardan Capital - Defense World
CervoMed (NASDAQ:CRVO) Given Buy Rating at D. Boral Capital - Defense World
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
CervoMed Announces Oral Presentation at 19th International - GlobeNewswire
CervoMed Inc. to Present Findings on Neflamapimod in Dementia with Lewy Bodies at AP/PD™ Conference 2025 - Nasdaq
CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™) - The Manila Times
CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders (AP/PD™) - TradingView
New Clinical Data: CervoMed's Breakthrough Dementia Drug Results Revealed at Global Conference - Stock Titan
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats - Seeking Alpha
CervoMed Stock: Extension Study Data In Dementia Is Potentially Exciting, With Caveats - Seeking Alpha
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Roth Capital Issues Negative Forecast for CervoMed Earnings - Defense World
Brokers Offer Predictions for CervoMed Q1 Earnings - Defense World
Q1 Earnings Forecast for CervoMed Issued By Roth Capital - Defense World
Is CervoMed Inc. (CRVO) Among the Best Short Squeeze Stocks to Buy According to Analysts? - Insider Monkey
CervoMed reports FY24 EPS ($2.02), consensus ($1.85) - MSN
CervoMed Inc (CRVO) Reports Q4 Net Loss of $16.3 Million, Grant Revenue at $9.7 Million - GuruFocus.com
Roth Mkm Issues Positive Forecast for CervoMed (NASDAQ:CRVO) Stock Price - Defense World
CervoMed (NASDAQ:CRVO) Given New $21.00 Price Target at Canaccord Genuity Group - Defense World
Best Biotech Stocks To Watch Now – March 17th - Defense World
10 Best Short Squeeze Stocks To Buy According to Analysts - Insider Monkey
CervoMed price target raised to $20 from $15 at Roth MKM - TipRanks
Following A Monumental March, Can CRVO Keep The Rally Going In April? - RTTNews
CervoMed sees cash runway into mid-2026 - MSN
CervoMed Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St
CervoMed price target raised to $21 from $12 at Canaccord - TipRanks
CervoMed Inc. (CRVO): The Best Short-Term Stock to Buy Right Now - Insider Monkey
Cervomed Inc. Faces Financial Hurdles Due to Regulatory Restrictions on Public Float - TipRanks
Small Cap Stocks To Watch NowMarch 13th - MarketBeat
Peering Into CervoMed's Recent Short Interest - Benzinga
CervoMed Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - MarketScreener
CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates - GlobeNewswire
CervoMed's Breakthrough in Lewy Body Dementia Treatment Shows Promise in Latest Financial Report - StockTitan
Why CervoMed Inc. (CRVO) Soared Last Week? - Insider Monkey
Cervomed Inc (CRVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.75%
2.22%
자본화:
|
볼륨(24시간):